Prelude Therapeutics appoints Katina Dorton to board of directors
PositiveFinancial Markets

Prelude Therapeutics has made a significant move by appointing Katina Dorton to its board of directors. This decision is noteworthy as Dorton brings extensive experience in the biotech industry, which could enhance the company's strategic direction and governance. Her expertise is expected to contribute positively to Prelude's mission of developing innovative therapies, making this appointment a promising step forward for the company and its stakeholders.
— Curated by the World Pulse Now AI Editorial System